CenExel Taps Ergomed CEO Pretorius to Drive Next-Growth Phase
Event summary
- Dr. Sy Pretorius named CenExel CEO effective May 1, 2026, succeeding Ryan Brooks who moves to board role.
- Pretorius brings 30+ years in clinical research leadership, including CEO of Ergomed Group and COO at EVERSANA.
- Focus areas: expanding strategic partnerships, therapeutic capabilities, and geographic footprint.
- Brooks' tenure emphasized operational foundation and differentiated therapeutic expertise.
The big picture
The appointment reflects a shift from operational stabilization to aggressive growth, aligning with private equity-backed CROs expanding service differentiation. Pretorius' transition from Ergomed—a mid-sized player in clinical trial services—suggests potential for cross-pollination of best practices between decentralized and traditional site networks.
What we're watching
- Strategic Partnerships
- How Pretorius' industry connections will accelerate CenExel's pharma sponsor relationships.
- Geographic Expansion
- The pace at which CenExel enters new markets under its 'centers of excellence' model.
- Operational Execution
- Whether Pretorius can maintain scientific rigor while scaling commercial operations.